BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:MVASI (bevacizumab-awwb) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of MVASI (bevacizumab-awwb)\, from ClinicalT
 rials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04185883-7746@assetmemo.bio
DTSTAMP:20261121T005020Z
DTSTART;VALUE=DATE:20261217
DTEND;VALUE=DATE:20261218
SUMMARY:MVASI (bevacizumab-awwb): Phase 1 readout est. (NCT04185883)
DESCRIPTION:MVASI (bevacizumab-awwb)\, phase 1.\nStudy: Sotorasib Activity 
 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBrea
 k 101)\nEstimated primary completion: 17 December 2026. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/bevacizumab-awwb#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT04185883
URL:https://assetmemo.bio/drug/bevacizumab-awwb#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05183984-7746@assetmemo.bio
DTSTAMP:20261121T005020Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:MVASI (bevacizumab-awwb): Phase 2 readout est. (NCT05183984)
DESCRIPTION:MVASI (bevacizumab-awwb)\, phase 2.\nStudy: Niraparib With beVA
 cizumab After Complete cytoreductioN in Patients With ovArian Cancer\nEsti
 mated primary completion: February 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/bevacizumab-awwb#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT05183984
URL:https://assetmemo.bio/drug/bevacizumab-awwb#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
